Single-Use Systems Continue to Gain Traction Among CMOs

摘要

Single-use bioprocessing equipment has made considerable progress in the past 10 years. An estimated 10% of current total worldwide bioprocessing capacity, or about 1.7 million liters, involves primarily single-use system (SUS) process lines. The market has grown from a few legacy products, such as plastic serum and media storage bags, tubing, and filter membranes, to the current situation where single-use technologies represent the majority of non-commercial applications in bioprocessing. This includes a wide variety of products and novel technologies currently available and in development.BioPlan's 15th Annual Report and Survey of Biopharmaceutical Manufacturing, 2018,1 which included responses from 222 biopharmaceutical manufacturers and CMOs in 22 countries and 130 bioprocessing suppliers or vendors, shows that single-use equipment is dominating small- and mid-scale bioprocessing and is being adopted for larger-scale commercial manufacturing.